Welcome to our dedicated page for JIN MED INTL LTD. SEC filings (Ticker: ZJYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Need clarity on how wheelchairs and other rehabilitation devices drive Jin Medical International Ltd’s margins? Start your research here. Our page brings Jin Medical International Ltd SEC filings explained simply, so you can move from raw disclosure to actionable insight without wading through hundreds of pages. Investors typically hunt for segment revenue tied to Japan, R&D outlays on next-generation mobility aids, and supply-chain risks—details that hide deep inside 10-Ks and 10-Qs.
Stock Titan’s AI reads every Jin Medical International Ltd quarterly earnings report 10-Q filing as soon as it hits EDGAR, summarizing revenue swings, cost trends, and unit shipments in plain English. The same engine delivers understanding Jin Medical International Ltd SEC documents with AI across the full spectrum of forms—so you’ll know when a new oxygen-machine patent shows up in an 8-K or when production capacity is updated in the annual report. Real-time alerts track Jin Medical International Ltd Form 4 insider transactions real-time, letting you see Jin Medical International Ltd executive stock transactions Form 4 minutes after insiders file.
Whether you’re screening for compliance shifts or scouting growth signals, you’ll find every document: a Jin Medical International Ltd annual report 10-K simplified; a concise Jin Medical International Ltd proxy statement executive compensation; or a headline summary with links for Jin Medical International Ltd 8-K material events explained. Our AI-powered summaries, key-metric extractions, and side-by-side comparisons turn filings into decisions—so you can complete a Jin Medical International Ltd earnings report filing analysis or monitor Jin Medical International Ltd insider trading Form 4 transactions without losing hours in dense text.
Jin Medical International Ltd. (Nasdaq: ZJYL) has filed a Form F-3 universal shelf registration that would allow it to issue up to $300 million of ordinary shares, warrants, debt securities, rights or units on a continuous or delayed basis. The filing gives the company maximum flexibility in timing, structure and pricing of future capital raises. Each specific offering will be detailed in a subsequent prospectus supplement.
The company’s current public float is approximately $34.4 million (based on 37.8 million non-affiliate shares at $0.91 on 30 Apr 2025). Because its float is below $75 million, General Instruction I.B.5 limits aggregate primary offerings under the F-3 to one-third of public float in any 12-month period—about $11.5 million at today’s level. Ordinary shares last traded at $0.6594 on 24 Jun 2025.
Jin Med is a Cayman holding company; operations are conducted in China through a variable-interest-entity (VIE), Changzhou Zhongjin Medical Equipment Co. Ltd. Investors buy equity in the Cayman entity and have only contractual, not ownership, exposure to the PRC operating company. The prospectus emphasizes extensive regulatory and enforcement risks associated with this structure, including potential PRC disallowance that could render the securities worthless.
The filing states the company is an emerging growth company; it is not currently subject to CAC cybersecurity review and, as an existing overseas issuer, is not immediately required to file with the CSRC for the shelf registration. Future offerings, however, must be filed with the CSRC within three business days of completion.
Key investor takeaways:
- Shelf capacity: up to $300 million, but annual usage capped by I.B.5.
- Potential dilution risk given current float and low share price.
- Material VIE, PRC policy and regulatory uncertainties.
- No immediate CAC or CSRC obstacles identified as of 15 May 2025.
Jin Medical International Ltd. (NASDAQ: ZJYL) filed a Form 6-K announcing the appointment of Dr. James Jiayuan Tong, age 51, as an Independent Director. Effective 20 June 2025, Dr. Tong becomes Chair of the Nominating & Corporate Governance Committee and joins the Audit and Compensation Committees, thereby increasing the proportion of independent oversight on all three key board panels.
Dr. Tong brings more than 20 years of cross-border experience in finance, investment banking, healthcare and academic research. Recent roles include founder of ThorBay Holdings (2022-present) and Venture Partner at Korea Investment Partners (2019-2022) with a focus on oncology, AR/VR, AI healthcare, medical devices and pre-IPO strategy. He has previously served as CFO and venture partner in both public and private companies, and has managed SEC compliance and M&A processes—skills directly relevant to committee responsibilities. Dr. Tong holds an M.D. from Peking University Health Science Center (1996) and a Ph.D. in Neuroscience from Stony Brook University (2001). There are no family relationships or related-party transactions requiring disclosure under Regulation S-K Item 404. The filing is expressly not incorporated by reference into other SEC filings.
The addition of an experienced, fully independent director with deep financial and healthcare expertise should strengthen Jin Medical’s governance framework and may enhance investor confidence; however, the filing contains no financial data or immediate operational changes.
FAQ
What is the current stock price of JIN MED INTL LTD. (ZJYL)?
What is the market cap of JIN MED INTL LTD. (ZJYL)?
What is the primary business activity of JIN MED INTL LTD?
Which product categories does the company offer?
How does JIN MED INTL LTD generate revenue?
What makes the company's product design and manufacturing process unique?
In which geographical market does the company have a major presence?
How does JIN MED INTL LTD differentiate itself from competitors?
What steps does the company take to ensure product quality and reliability?
